Nanostructured Natural Bioactives: A Promising Frontier for MASLD Therapy

Background: Natural bioactives derived from medicinal plants and dietary sources have long been used to manage metabolic and hepatic disorders. However, their application in metabolic dysfunction-associated steatotic liver disease (MASLD) is restricted by poor solubility, instability, low bioavailability, rapid metabolism, and insufficient hepatic exposure. This review evaluates the pharmacological mechanisms and therapeutic potential of nanostructured natural bioactives for MASLD. Methods: Published preclinical and clinical evidence on natural bioactives and their nanostructured formulations for MASLD was narratively reviewed. Evidence was synthesized according to nanocarrier type, pharmacokinetic advantages, mechanisms of action, therapeutic outcomes, safety, and clinical translation. Results: The included studies primarily covered three categories: nanostructured natural small-molecule bioactives, bioactive fractions, and single-source therapeutics. Small-molecule bioactives constituted the largest group, encompassing flavonoids, polyphenols, terpenoids, alkaloids, and lignans. Liposomes, nanoemulsions, polymeric nanoparticles, and micelles were the principal delivery platforms used to improve effective exposure through encapsulation, protection, and controlled release. Mechanisms included modulation of AMPK, SREBP-1c/FAS-, and PPARα/CPT-1-related lipid metabolism, suppression of NF-κB-associated inflammation, and enhancement of Nrf2-related antioxidant defenses, collectively attenuating hepatic lipid accumulation and injury. Nanostructured bioactive fractions and single-source therapeutics additionally involved multicomponent interactions, intestinal barrier protection, and gut–liver axis modulation. Nanostructured small-molecule bioactives showed translational promise, with oral nano-curcumin providing preliminary clinical evidence, although its additional benefits on hepatic fat content were inconsistent. Naturally derived vesicle-like nanoparticles also showed potential, but their compositional standardization, in vivo behavior, and long-term safety require further investigation. Conclusions: Nanostructuring may improve the pharmacokinetic performance and pharmacological efficacy of natural bioactives against MASLD. Future studies should prioritize standardized formulation characterization, dose–exposure–response relationships, direct comparisons with free bioactives, long-term safety, and clinical trials.

Authors

Institutions

Publication Details

Journal
Pharmaceuticals
Published
2026-11-17
DOI
https://doi.org/10.3390/ph19111832
Primary Topic
Liver Disease Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Nanostructured Natural Bioactives: A Promising Frontier for MASLD Therapy

Jia Geng, Lili Shen, Xin Xin, Lin Ru-tao et al.
4 links
Pharmaceuticals
Liver Disease Diagnosis and Treatment
article

Nanostructured Natural Bioactives: A Promising Frontier for MASLD Therapy

Jia Geng, Lili Shen, Xin Xin, Lin Ru-tao, Chen Zou, Lei Shi, Qin-Mei Sun, Ren-Qiang Zeng, Xu-Ting Shen, Qin Feng
article en

Abstract

Background: Natural bioactives derived from medicinal plants and dietary sources have long been used to manage metabolic and hepatic disorders. However, their application in metabolic dysfunction-associated steatotic liver disease (MASLD) is restricted by poor solubility, instability, low bioavailability, rapid metabolism, and insufficient hepatic exposure. This review evaluates the pharmacological mechanisms and therapeutic potential of nanostructured natural bioactives for MASLD. Methods: Published preclinical and clinical evidence on natural bioactives and their nanostructured formulations for MASLD was narratively reviewed. Evidence was synthesized according to nanocarrier type, pharmacokinetic advantages, mechanisms of action, therapeutic outcomes, safety, and clinical translation. Results: The included studies primarily covered three categories: nanostructured natural small-molecule bioactives, bioactive fractions, and single-source therapeutics. Small-molecule bioactives constituted the largest group, encompassing flavonoids, polyphenols, terpenoids, alkaloids, and lignans. Liposomes, nanoemulsions, polymeric nanoparticles, and micelles were the principal delivery platforms used to improve effective exposure through encapsulation, protection, and controlled release. Mechanisms included modulation of AMPK, SREBP-1c/FAS-, and PPARα/CPT-1-related lipid metabolism, suppression of NF-κB-associated inflammation, and enhancement of Nrf2-related antioxidant defenses, collectively attenuating hepatic lipid accumulation and injury. Nanostructured bioactive fractions and single-source therapeutics additionally involved multicomponent interactions, intestinal barrier protection, and gut–liver axis modulation. Nanostructured small-molecule bioactives showed translational promise, with oral nano-curcumin providing preliminary clinical evidence, although its additional benefits on hepatic fat content were inconsistent. Naturally derived vesicle-like nanoparticles also showed potential, but their compositional standardization, in vivo behavior, and long-term safety require further investigation. Conclusions: Nanostructuring may improve the pharmacokinetic performance and pharmacological efficacy of natural bioactives against MASLD. Future studies should prioritize standardized formulation characterization, dose–exposure–response relationships, direct comparisons with free bioactives, long-term safety, and clinical trials.

PharmaceuticalsVol. 19(11)
Sichuan University (CN), West China Medical Center of Sichuan University (CN), West China Hospital of Sichuan University (CN), Shanghai University of Traditional Chinese Medicine (CN), Shuguang Hospital (CN), State Key Laboratory of Biotherapy (CN)
Shanghai University of Traditional Chinese Medicine, Shanghai Pudong New Area Health Commission
Good health and well-being
Liver Disease Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon